;PMID: 11422031
;source_file_823.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..157] = [t:45..157]
;2)section:[e:161..231] = [t:161..231]
;3)section:[e:235..306] = [t:235..306]
;4)sentence:[e:310..321] = [t:310..321]
;5)sentence:[e:322..519] = [t:322..519]
;6)sentence:[e:520..531] = [t:520..531]
;7)sentence:[e:533..875] = [t:533..875]
;8)sentence:[e:876..884] = [t:876..884]
;9)sentence:[e:885..1027] = [t:885..1027]
;10)sentence:[e:1028..1036] = [t:1028..1036]
;11)sentence:[e:1037..1177] = [t:1037..1177]
;12)sentence:[e:1178..1430] = [t:1178..1430]
;13)sentence:[e:1431..1657] = [t:1431..1657]
;14)sentence:[e:1658..1670] = [t:1658..1670]
;15)sentence:[e:1671..1767] = [t:1671..1767]
;16)sentence:[e:1768..1915] = [t:1768..1915]
;17)section:[e:1919..1964] = [t:1919..1964]

;section 0 Span:0..39
;Br J Dermatol. 2001 Jun;144(6):1127-32.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..13] Dermatol) (.:[13..14] .)
        (CD:[15..19] 2001) (CC:[20..28] Jun;144-LRB-) (CD:[28..30] 6-RRB-)
        (CD:[30..35] :1127) (HYPH:[35..36] -) (CD:[36..38] 32) (.:[38..39] .)))

;sentence 1 Span:45..157
;Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by
;bath  PUVA in dermatological patients.
;[51..73]:cyp450:"cytochrome P450 CYP1A2"
(SENT
  (S-HLN
    (NP-SBJ-3
      (NP (NN:[45..50] Liver) (NN:[51..61] cytochrome) (NN:[62..66] P450))
      (NP (NN:[67..73] CYP1A2)))
    (VP (VBZ:[74..76] is)
      (ADVP (RB:[77..85] markedly))
      (VP
        (VP (VBN:[86..95] inhibited)
          (NP-3 (-NONE-:[95..95] *))
          (PP=2 (IN:[96..98] by)
            (NP-LGS (JJ:[99..107] systemic)
              (NML-1 (-NONE-:[107..107] *P*))))
          (PP-LOC-4 (-NONE-:[107..107] *RNR*)))
        (CC:[108..111] but) (RB:[112..115] not)
        (VP
          (PP=2 (IN:[116..118] by)
            (NP-LGS (NN:[119..123] bath)
              (NML-1 (NN:[125..129] PUVA))))
          (PP-LOC-4 (-NONE-:[129..129] *RNR*)))
        (PP-LOC-4 (IN:[130..132] in)
          (NP (JJ:[133..147] dermatological) (NNS:[148..156] patients)))))
    (.:[156..157] .)))

;section 2 Span:161..231
;Tantcheva-Poor I, Servera-Llaneras M, Scharffetter-Kochanek K, Fuhr U.
(SEC
  (FRAG (NNP:[161..170] Tantcheva) (HYPH:[170..171] -) (NNP:[171..175] Poor)
        (NNP:[176..177] I) (,:[177..178] ,) (NNP:[179..186] Servera)
        (HYPH:[186..187] -) (NNP:[187..195] Llaneras) (NNP:[196..198] M,)
        (NNP:[199..211] Scharffetter) (HYPH:[211..212] -)
        (NNP:[212..220] Kochanek) (NNP:[221..222] K) (,:[222..223] ,)
        (NNP:[224..228] Fuhr) (NNP:[229..231] U.)))

;section 3 Span:235..306
;Institute for Pharmacology, Clinical Pharmacology, 50931 Koln, Germany.
(SEC
  (FRAG (NNP:[235..244] Institute) (IN:[245..248] for)
        (NNP:[249..261] Pharmacology) (,:[261..262] ,) (NNP:[263..271] Clinical)
        (NNP:[272..284] Pharmacology) (,:[284..285] ,) (CD:[286..291] 50931)
        (NNPS:[292..296] Koln) (,:[296..297] ,) (NNP:[298..305] Germany)
        (.:[305..306] .)))

;sentence 4 Span:310..321
;BACKGROUND:
(SENT
  (NP (NN:[310..320] BACKGROUND) (::[320..321] :)))

;sentence 5 Span:322..519
;Methoxsalen (8-MOP) may cause important pharmacokinetic drug  interactions as
;it has been shown to inhibit and/or induce several  drug-metabolizing enzymes
;in vitro, in animal models and in humans.
;[322..333]:substance:"Methoxsalen"
;[335..340]:substance:"8-MOP"
;[378..382]:substance:"drug"
;[452..477]:substance:"drug-metabolizing enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[322..333] Methoxsalen))
      (NP (-LRB-:[334..335] -LRB-) (NN:[335..340] 8-MOP)
          (-RRB-:[340..341] -RRB-)))
    (VP (MD:[342..345] may)
      (VP (VB:[346..351] cause)
        (NP (JJ:[352..361] important) (JJ:[362..377] pharmacokinetic)
            (NN:[378..382] drug) (NNS:[384..396] interactions))
        (SBAR-ADV (IN:[397..399] as)
          (S
            (NP-SBJ-1 (PRP:[400..402] it))
            (VP (VBZ:[403..406] has)
              (VP (VBN:[407..411] been)
                (VP (VBN:[412..417] shown)
                  (S
                    (NP-SBJ-1 (-NONE-:[417..417] *))
                    (VP (TO:[418..420] to)
                      (VP (VB:[421..428] inhibit) (CC:[429..435] and/or)
                          (VB:[436..442] induce)
                        (NP (JJ:[443..450] several)
                          
                          (ADJP (NN:[452..456] drug) (HYPH:[456..457] -)
                                (VBG:[457..469] metabolizing))
                          (NNS:[470..477] enzymes))
                        (ADVP (FW:[478..480] in) (FW:[481..486] vitro))
                        (,:[486..487] ,)
                        (PP-LOC
                          (PP (IN:[488..490] in)
                            (NP (NN:[491..497] animal) (NNS:[498..504] models)))
                          (CC:[505..508] and)
                          (PP (IN:[509..511] in)
                            (NP (NNS:[512..518] humans))))))))))))))
    (.:[518..519] .)))

;sentence 6 Span:520..531
;OBJECTIVES:
(SENT
  (NP (NNS:[520..530] OBJECTIVES) (::[530..531] :)))

;sentence 7 Span:533..875
;In order to assess the clinical importance of acute and chronic 8-MOP effects
;on  the liver cytochrome P-450 enzyme CYP1A2 in vivo, we measured caffeine
;clearance  in dermatological patients before the onset of systemic or bath
;psoralen +  ultraviolet A radiation (PUVA) (8-MOP + UVA) therapy, on the
;first day and after  1 week of treatment.
;[597..602]:substance:"8-MOP"
;[625..655]:cyp450:"cytochrome P-450 enzyme CYP1A2"
;[677..685]:substance:"caffeine"
;[761..769]:substance:"psoralen"
;[805..810]:substance:"8-MOP"
;[834..839]:quantitative-value:"first"
;[840..843]:quantitative-units:"day"
;[855..856]:quantitative-value:"1"
;[857..861]:quantitative-units:"week"
(SENT
  (S
    (SBAR-PRP (IN:[533..535] In) (NN:[536..541] order)
      (S
        (NP-SBJ (-NONE-:[541..541] *))
        (VP (TO:[542..544] to)
          (VP (VB:[545..551] assess)
            (NP
              (NP (DT:[552..555] the) (JJ:[556..564] clinical)
                  (NN:[565..575] importance))
              (PP (IN:[576..578] of)
                (NP
                  (NP
                    (NP (JJ:[579..584] acute)
                      (NML-1 (-NONE-:[584..584] *P*)))
                    (CC:[585..588] and)
                    (NP (JJ:[589..596] chronic)
                      (NML-1 (NN:[597..602] 8-MOP) (NNS:[603..610] effects))))
                  (PP (IN:[611..613] on)
                    (NP
                      (NP (DT:[615..618] the) (NN:[619..624] liver)
                        (NML (NN:[625..635] cytochrome) (NN:[636..641] P-450))
                        (NN:[642..648] enzyme))
                      (NP (NN:[649..655] CYP1A2)))))))
            (ADVP (FW:[656..658] in) (FW:[659..663] vivo))))))
    (,:[663..664] ,)
    (NP-SBJ (PRP:[665..667] we))
    (VP (VBD:[668..676] measured)
      (NP (NN:[677..685] caffeine) (NN:[686..695] clearance))
      (PP-LOC (IN:[697..699] in)
        (NP (JJ:[700..714] dermatological) (NNS:[715..723] patients)))
      (PP-TMP (IN:[724..730] before)
        (NP
          (NP (DT:[731..734] the) (NN:[735..740] onset))
          (PP (IN:[741..743] of)
            (NP
              (NP
                (NML (JJ:[744..752] systemic)
                  (NML-3 (-NONE-:[752..752] *P*)))
                (NML-4 (-NONE-:[752..752] *P*)))
              (CC:[753..755] or)
              (NP
                (NML (NN:[756..760] bath)
                  (NML-3
                    (NML
                      (NML
                        (NP (NN:[761..769] psoralen))
                        (SYM:[770..771] +)
                        (NP
                          (NML (JJ:[773..784] ultraviolet) (NN:[785..786] A))
                          (NN:[787..796] radiation)))
                      (NML (-LRB-:[797..798] -LRB-) (NN:[798..802] PUVA)
                           (-RRB-:[802..803] -RRB-)))
                    (PRN (-LRB-:[804..805] -LRB-)
                      (NP (NN:[805..810] 8-MOP) (SYM:[811..812] +)
                          (NN:[813..816] UVA))
                      (-RRB-:[816..817] -RRB-))))
                (NML-4 (NN:[818..825] therapy)))))))
      (,:[825..826] ,)
      (PP-TMP
        (PP (IN:[827..829] on)
          (NP
            (NP (DT:[830..833] the) (JJ:[834..839] first) (NN:[840..843] day))
            (PP-2 (-NONE-:[843..843] *P*))))
        (CC:[844..847] and)
        (PP (IN:[848..853] after)
          (NP
            (NP (CD:[855..856] 1) (NN:[857..861] week))
            (PP-2 (IN:[862..864] of)
              (NP (NN:[865..874] treatment)))))))
    (.:[874..875] .)))

;sentence 8 Span:876..884
;METHODS:
(SENT
  (NP (NNS:[876..883] METHODS) (::[883..884] :)))

;sentence 9 Span:885..1027
;Data from four patients with systemic PUVA and  seven patients with bath PUVA
;were available (age range 23-71 years, five women  and six men).
;[989..994]:quantitative-value:"23-71"
;[995..1000]:quantitative-units:"years"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[885..889] Data))
      (PP (IN:[890..894] from)
        (NP
          (NP
            (NP (CD:[895..899] four) (NNS:[900..908] patients))
            (PP (IN:[909..913] with)
              (NP (JJ:[914..922] systemic) (NN:[923..927] PUVA))))
          (CC:[928..931] and)
          (NP
            (NP (CD:[933..938] seven) (NNS:[939..947] patients))
            (PP (IN:[948..952] with)
              (NP (NN:[953..957] bath) (NN:[958..962] PUVA)))))))
    (VP (VBD:[963..967] were)
      (ADJP-PRD (JJ:[968..977] available))
      (PRN (-LRB-:[978..979] -LRB-)
        (FRAG
          (S
            (NP-SBJ (NN:[979..982] age) (NN:[983..988] range))
            (NP-PRD
              (QP (CD:[989..991] 23) (HYPH:[991..992] -) (CD:[992..994] 71))
              (NNS:[995..1000] years)))
          (,:[1000..1001] ,)
          (NP
            (NP (CD:[1002..1006] five) (NNS:[1007..1012] women))
            (CC:[1014..1017] and)
            (NP (CD:[1018..1021] six) (NNS:[1022..1025] men))))
        (-RRB-:[1025..1026] -RRB-)))
    (.:[1026..1027] .)))

;sentence 10 Span:1028..1036
;RESULTS:
(SENT
  (NP (NNS:[1028..1035] RESULTS) (::[1035..1036] :)))

;sentence 11 Span:1037..1177
;For all of the patients, individual pre-PUVA caffeine  clearance values were
;above the lower limit of previously assessed reference  ranges.
;[1082..1090]:substance:"caffeine"
(SENT
  (S
    (PP (IN:[1037..1040] For)
      (NP
        (NP (DT:[1041..1044] all))
        (PP (IN:[1045..1047] of)
          (NP (DT:[1048..1051] the) (NNS:[1052..1060] patients)))))
    (,:[1060..1061] ,)
    (NP-SBJ (JJ:[1062..1072] individual)
      (NML (AFX:[1073..1076] pre) (HYPH:[1076..1077] -) (NN:[1077..1081] PUVA))
      (NML (NN:[1082..1090] caffeine) (NN:[1092..1101] clearance))
      (NNS:[1102..1108] values))
    (VP (VBD:[1109..1113] were)
      (PP-PRD (IN:[1114..1119] above)
        (NP
          (NP (DT:[1120..1123] the) (JJR:[1124..1129] lower)
              (NN:[1130..1135] limit))
          (PP (IN:[1136..1138] of)
            (NP
              (ADJP (RB:[1139..1149] previously) (VBN:[1150..1158] assessed))
              (NN:[1159..1168] reference) (NNS:[1170..1176] ranges))))))
    (.:[1176..1177] .)))

;sentence 12 Span:1178..1430
;Systemic PUVA markedly decreased caffeine clearance by factors of 0.17  [90%
;confidence interval (CI) 0.07-0.42] on the first day and 0.14 (90% CI 
;0.05-0.36) after 1 week of treatment, respectively, and values thus dropped 
;below the reference ranges.
;[1211..1219]:substance:"caffeine"
;[1244..1248]:quantitative-value:"0.17"
;[1251..1254]:quantitative-value:"90%"
;[1276..1278]:quantitative-name:"CI"
;[1280..1289]:quantitative-value:"0.07-0.42"
;[1312..1316]:quantitative-value:"0.14"
;[1318..1321]:quantitative-value:"90%"
;[1322..1324]:quantitative-name:"CI"
;[1326..1335]:quantitative-value:"0.05-0.36"
;[1343..1344]:quantitative-value:"1"
;[1345..1349]:quantitative-units:"week"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[1178..1186] Systemic) (NN:[1187..1191] PUVA))
      (VP
        (VP
          (ADVP (RB:[1192..1200] markedly))
          (VBD:[1201..1210] decreased)
          (NP (NN:[1211..1219] caffeine) (NN:[1220..1229] clearance))
          (PP-EXT (IN:[1230..1232] by)
            (NP
              (NP (NNS:[1233..1240] factors))
              (PP (IN:[1241..1243] of)
                (NP=2 (CD:[1244..1248] 0.17)
                  (PRN (-LRB-:[1250..1251] -LSB-)
                    (S
                      (NP-SBJ
                        (NML (CD:[1251..1253] 90) (NN:[1253..1254] %))
                        (NML
                          (NML (NN:[1255..1265] confidence)
                               (NN:[1266..1274] interval))
                          (NML (-LRB-:[1275..1276] -LRB-) (NN:[1276..1278] CI)
                               (-RRB-:[1278..1279] -RRB-))))
                      (NP-PRD
                        (QP (CD:[1280..1284] 0.07) (HYPH:[1284..1285] -)
                            (CD:[1285..1289] 0.42))))
                    (-RRB-:[1289..1290] -RSB-))))))
          (PP-TMP=1 (IN:[1291..1293] on)
            (NP
              (NP (DT:[1294..1297] the) (JJ:[1298..1303] first)
                  (NN:[1304..1307] day))
              (PP-3 (-NONE-:[1307..1307] *P*)))))
        (CC:[1308..1311] and)
        (VP
          (NP=2 (CD:[1312..1316] 0.14)
            (PRN (-LRB-:[1317..1318] -LRB-)
              (S
                (NP-SBJ
                  (NML (CD:[1318..1320] 90) (NN:[1320..1321] %))
                  (NN:[1322..1324] CI))
                (NP-PRD
                  (QP (CD:[1326..1330] 0.05) (HYPH:[1330..1331] -)
                      (CD:[1331..1335] 0.36))))
              (-RRB-:[1335..1336] -RRB-)))
          (PP-TMP=1 (IN:[1337..1342] after)
            (NP
              (NP (CD:[1343..1344] 1) (NN:[1345..1349] week))
              (PP-3 (IN:[1350..1352] of)
                (NP (NN:[1353..1362] treatment))))))
        (,:[1362..1363] ,)
        (ADVP (RB:[1364..1376] respectively))))
    (,:[1376..1377] ,) (CC:[1378..1381] and)
    (S
      (NP-SBJ (NNS:[1382..1388] values))
      (ADVP (RB:[1389..1393] thus))
      (VP (VBD:[1394..1401] dropped)
        (PP (IN:[1403..1408] below)
          (NP (DT:[1409..1412] the) (NN:[1413..1422] reference)
              (NNS:[1423..1429] ranges)))))
    (.:[1429..1430] .)))

;sentence 13 Span:1431..1657
;In contrast, bath PUVA had no obvious effect on  pre-PUVA clearance values as
;the latter changed by factors of 1.00 (90% CI  0.81-1.23) and 1.05 (90% CI
;0.75-1.49) on the first day and after 1 week of  treatment, respectively.
;[1542..1546]:quantitative-value:"1.00"
;[1548..1551]:quantitative-value:"90%"
;[1552..1554]:quantitative-name:"CI"
;[1556..1565]:quantitative-value:"0.81-1.23"
;[1571..1575]:quantitative-value:"1.05"
;[1577..1580]:quantitative-value:"90%"
;[1581..1583]:quantitative-name:"CI"
;[1584..1593]:quantitative-value:"0.75-1.49"
;[1602..1607]:quantitative-value:"first"
;[1608..1611]:quantitative-units:"day"
;[1622..1623]:quantitative-value:"1"
;[1624..1628]:quantitative-units:"week"
(SENT
  (S
    (PP (IN:[1431..1433] In)
      (NP (NN:[1434..1442] contrast)))
    (,:[1442..1443] ,)
    (NP-SBJ (NN:[1444..1448] bath) (NN:[1449..1453] PUVA))
    (VP (VBD:[1454..1457] had)
      (NP
        (NP (DT:[1458..1460] no) (JJ:[1461..1468] obvious)
            (NN:[1469..1475] effect))
        (PP (IN:[1476..1478] on)
          (NP
            (NML (AFX:[1480..1483] pre) (HYPH:[1483..1484] -)
                 (NN:[1484..1488] PUVA))
            (NN:[1489..1498] clearance) (NNS:[1499..1505] values))))
      (SBAR-ADV (IN:[1506..1508] as)
        (S
          (NP-SBJ (DT:[1509..1512] the) (JJ:[1513..1519] latter))
          (VP (VBD:[1520..1527] changed)
            (PP-EXT (IN:[1528..1530] by)
              (NP
                (NP (NNS:[1531..1538] factors))
                (PP (IN:[1539..1541] of)
                  (NP
                    (NP (CD:[1542..1546] 1.00)
                      (PRN (-LRB-:[1547..1548] -LRB-)
                        (S
                          (NP-SBJ
                            (NML (CD:[1548..1550] 90) (NN:[1550..1551] %))
                            (NN:[1552..1554] CI))
                          (NP-PRD
                            (QP (CD:[1556..1560] 0.81) (HYPH:[1560..1561] -)
                                (CD:[1561..1565] 1.23))))
                        (-RRB-:[1565..1566] -RRB-)))
                    (CC:[1567..1570] and)
                    (NP (CD:[1571..1575] 1.05)
                      (PRN (-LRB-:[1576..1577] -LRB-)
                        (S
                          (NP-SBJ
                            (NML (CD:[1577..1579] 90) (NN:[1579..1580] %))
                            (NN:[1581..1583] CI))
                          (NP-PRD
                            (QP (CD:[1584..1588] 0.75) (HYPH:[1588..1589] -)
                                (CD:[1589..1593] 1.49))))
                        (-RRB-:[1593..1594] -RRB-)))))))
            (PP-TMP
              (PP (IN:[1595..1597] on)
                (NP
                  (NP (DT:[1598..1601] the) (JJ:[1602..1607] first)
                      (NN:[1608..1611] day))
                  (PP-1 (-NONE-:[1611..1611] *P*))))
              (CC:[1612..1615] and)
              (PP (IN:[1616..1621] after)
                (NP
                  (NP (CD:[1622..1623] 1) (NN:[1624..1628] week))
                  (PP-1 (IN:[1629..1631] of)
                    (NP (NN:[1633..1642] treatment))))))
            (,:[1642..1643] ,)
            (ADVP (RB:[1644..1656] respectively))))))
    (.:[1656..1657] .)))

;sentence 14 Span:1658..1670
;CONCLUSIONS:
(SENT
  (NP (NNS:[1658..1669] CONCLUSIONS) (::[1669..1670] :)))

;sentence 15 Span:1671..1767
;Systemic PUVA causes pronounced inhibition  of liver CYP1A2, while bath PUVA
;has no such effect.
;[1724..1730]:cyp450:"CYP1A2"
(SENT
  (S
    (NP-SBJ (JJ:[1671..1679] Systemic) (NN:[1680..1684] PUVA))
    (VP (VBZ:[1685..1691] causes)
      (NP
        (NP (JJ:[1692..1702] pronounced) (NN:[1703..1713] inhibition))
        (PP (IN:[1715..1717] of)
          (NP (NN:[1718..1723] liver) (NN:[1724..1730] CYP1A2))))
      (,:[1730..1731] ,)
      (SBAR-ADV (IN:[1732..1737] while)
        (S
          (NP-SBJ (NN:[1738..1742] bath) (NN:[1743..1747] PUVA))
          (VP (VBZ:[1748..1751] has)
            (NP (DT:[1752..1754] no) (JJ:[1755..1759] such)
                (NN:[1760..1766] effect))))))
    (.:[1766..1767] .)))

;sentence 16 Span:1768..1915
;The extent of interaction  makes a dose adjustment for most CYP1A2 substrates
;such as theophylline  mandatory in patients undergoing systemic PUVA.
;[1828..1834]:cyp450:"CYP1A2"
;[1835..1845]:substance:"substrates"
;[1854..1866]:substance:"theophylline"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1768..1771] The) (NN:[1772..1778] extent))
      (PP (IN:[1779..1781] of)
        (NP (NN:[1782..1793] interaction))))
    (VP (VBZ:[1795..1800] makes)
      (S
        (NP-SBJ
          (NP (DT:[1801..1802] a) (NN:[1803..1807] dose)
              (NN:[1808..1818] adjustment))
          (PP (IN:[1819..1822] for)
            (NP
              (NP (JJS:[1823..1827] most) (NN:[1828..1834] CYP1A2)
                  (NNS:[1835..1845] substrates))
              (PP (JJ:[1846..1850] such) (IN:[1851..1853] as)
                (NP (NN:[1854..1866] theophylline))))))
        (ADJP-PRD (JJ:[1868..1877] mandatory)))
      (PP-LOC (IN:[1878..1880] in)
        (NP
          (NP (NNS:[1881..1889] patients))
          (VP (VBG:[1890..1900] undergoing)
            (NP (JJ:[1901..1909] systemic) (NN:[1910..1914] PUVA))))))
    (.:[1914..1915] .)))

;section 17 Span:1919..1964
;PMID: 11422031 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1919..1923] PMID) (::[1923..1924] :) (CD:[1925..1933] 11422031)
        (IN:[1934..1935] -LSB-) (NNP:[1935..1941] PubMed) (HYPH:[1942..1943] -)
        (JJ:[1944..1951] indexed) (IN:[1952..1955] for)
        (NNP:[1956..1964] MEDLINE-RSB-)))
